Skip to content

US · CINGW · BIOTECHNOLOGY

Cingulate Inc. (CINGW) intrinsic value and stock valuation

$0.00as of 2026-11-21 · Mkt cap 60.11K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cingulate Inc. DCF and intrinsic value

InvestorsCraft values CINGW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CINGW’s statements →

Cingulate Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Kansas City, KS 66205 cingulate.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-22.45M
20192025
Free cash flow
-$-17.41M
20192025
Total equity
$2.51M+14.2% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-19.94M-$-15.64M-$-22.76M-$-17.5M-$-20.68M
Net income-$-22.45M-$-16.56M-$-23.53M-$-17.68M-$-20.71M
EPSd-$-4.13M-$-4.35M-$-10.41M-$-12.54M-$-14.69M
Operating cash flow-$-17.25M-$-18.45M-$-15.03M-$-15.88M-$-10.43M
Capital expenditure-$-160K-$-210K-$-220K-$-150K-$-810K
Free cash flow-$-17.41M-$-18.66M-$-15.26M-$-16.04M-$-11.25M
Total assets$15.1M$14.9M$3.49M$11.4M$22.9M
Total debt$8.79M$5.1M$3.51M$5.87M$1.19M
Net debt-$-2.17M-$-7.11M$3.46M$510K-$-15.3M
Total equity$2.51M$7.46M-$-6.87M$3.88M$20.8M
Cash and short-term investments$11M$12.2M$50K$5.36M$16.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$9.77M$9.45M$15.5M$9M$8.41M
Selling, general and administrative expenses$10.2M$6.2M$7.27M$8.51M$12.3M
Other expenses$0.00-$0.00-$0.00-$0.00-$0.00
Operating expenses$19.9M$15.6M$22.8M$17.5M$20.7M
Cost and expenses$19.9M$15.6M$22.8M$17.5M$20.7M
Interest income$370K$0.00$780K$0.00$0.00
Interest expense$920K$0.00$0.00$170K$30K
Depreciation and amortization$540K$650K$580K$390K$710K
Ebitda-$-19.4M-$-14.99M-$-22.18M-$-17.11M-$-19.97M
Operating income-$-19.94M-$-15.64M-$-22.76M-$-17.5M-$-20.68M
Total other income/expenses, net-$-2.51M-$-910K-$-780K-$-170K-$-30K
Income before tax-$-22.45M-$-16.56M-$-23.53M-$-17.68M-$-20.71M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-22.45M-$-16.56M-$-23.53M-$-17.68M-$-20.71M
Weighted average shares outstanding$5.43M$3.81M$2.26M$1.41M$1.41M
Weighted average diluted shares outstanding$5.43M$3.81M$2.26M$1.41M$1.41M
Balance sheet
20252024202320222021
Cash and short-term investments$11M$12.2M$50K$5.36M$16.5M
Net receivables$10K$30K$10K$230K$690K
Inventory$0.00$0.00$0.00$100K$0.00
Total current assets$12M$12.7M$580K$7.87M$18.9M
Property, plant and equipment, net$3.07M$2.2M$2.91M$3.54M$4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.07M$2.2M$2.91M$3.54M$4M
Total assets$15.1M$14.9M$3.49M$11.4M$22.9M
Accounts payable$2.04M$1.27M$5.2M$760K$260K
Short-term debt$6.53M$2.66M$3.38M$5.36M$330K
Deferred revenue$0.00$0.00$0.00$0.00$600K
Total current liabilities$10.3M$4.97M$10.2M$7.01M$1.18M
Long-term debt$2.25M$2.44M$140K$510K$870K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.25M$2.44M$140K$510K$870K
Capital lease obligations$1.34M$140K$510K$870K$880K
Total liabilities$12.6M$7.41M$10.4M$7.52M$2.04M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-132.38M-$-108.49M-$-92.94M-$-69.41M-$-51.73M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.51M$7.46M-$-6.87M$3.88M$20.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$8.79M$5.1M$3.51M$5.87M$1.19M
Net debt-$-2.17M-$-7.11M$3.46M$510K-$-15.3M
Cash flow statement
20252024202320222021
Net income-$-22.45M-$-15.55M-$-23.53M-$-17.68M-$-20.71M
Depreciation and amortization$540K$650K$580K$390K$710K
Stock-based compensation$0.00$1M$810K$800K$12.8M
Change in working capital$830K-$-4.55M$7.1M$600K-$-3.21M
Accounts receivable$20K-$-10K$220K$1.25M-$-1.86M
Inventory$0.00$0.00$0.00-$-1.25M$0.00
Accounts payable$0.00$0.00$0.00$790K$0.00
Net cash provided by operating activities-$-17.25M-$-18.45M-$-15.03M-$-15.88M-$-10.43M
Investments in property, plant and equipment-$-160K-$-210K-$-220K-$-150K-$-810K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-160K-$-210K-$-220K-$-150K-$-810K
Common stock issued$10.2M$25.9M$6.97M-$-90K$20.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.2M$30.8M$9.95M$4.9M$26.5M
Net change in cash-$-1.26M$12.2M-$-5.3M-$-11.14M$15.3M
Cash at end of period$11M$12.2M$50K$5.36M$16.5M
Operating cash flow-$-17.25M-$-18.45M-$-15.03M-$-15.88M-$-10.43M
Capital expenditure-$-160K-$-210K-$-220K-$-150K-$-810K
Free cash flow-$-17.41M-$-18.66M-$-15.26M-$-16.04M-$-11.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cingulate Inc.

        Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.

        CEO
        Shane J. Schaffer
        Employees
        14
        Beta
        -0.91

        Explore

        Frequently asked questions

        What is the intrinsic value of Cingulate Inc. (CINGW)?

        InvestorsCraft does not currently publish an intrinsic value for CINGW. How the IC value is calculated.

        Is CINGW undervalued?

        InvestorsCraft does not publish an undervaluation signal for CINGW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.